| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The following is a summary of awards outstanding as of September 30, 2026 and 2025, which are not included in the computation of basic and diluted weighted average shares:
|
|
|
|
|
|
|
|
|
|
|
Three and nine months ended
September 30, |
|
|
|
2026 |
|
|
2025 |
|
Stock options (excluding exercisable penny stock options) |
|
|
9,639,598 |
|
|
|
8,912,143 |
|
Restricted stock units |
|
|
— |
|
|
|
519,947 |
|
Warrants |
|
|
6,545,785 |
|
|
|
5,827,035 |
|
Performance-based restricted stock units |
|
|
2,800,000 |
|
|
|
— |
|
Total |
|
|
18,985,383 |
|
|
|
15,259,125 |
|
|
| Schedule of Segment Reporting Information, by Segment |
In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September 30, |
|
|
Nine months ended September 30, |
|
(in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Employee expenses |
|
$ |
2,046 |
|
|
$ |
2,949 |
|
|
$ |
8,293 |
|
|
$ |
8,821 |
|
Research and Development (excluding employee expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
Consulting and professional fees |
|
|
319 |
|
|
|
546 |
|
|
|
1,192 |
|
|
|
1,220 |
|
Clinical study expenses |
|
|
19 |
|
|
|
92 |
|
|
|
278 |
|
|
|
297 |
|
Product development |
|
|
4 |
|
|
|
677 |
|
|
|
207 |
|
|
|
2,032 |
|
Other* |
|
|
315 |
|
|
|
313 |
|
|
|
903 |
|
|
|
951 |
|
Total Research and development expense |
|
$ |
657 |
|
|
$ |
1,628 |
|
|
$ |
2,580 |
|
|
$ |
4,500 |
|
Selling, general and administrative expense (excluding employee expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
513 |
|
|
|
477 |
|
|
|
1,570 |
|
|
|
1,804 |
|
Commercialization readiness expenses |
|
|
241 |
|
|
|
236 |
|
|
|
822 |
|
|
|
704 |
|
Total Selling, general and administrative expense |
|
|
754 |
|
|
|
713 |
|
|
|
2,392 |
|
|
|
2,508 |
|
Total operating expenses |
|
$ |
3,457 |
|
|
$ |
5,290 |
|
|
$ |
13,265 |
|
|
$ |
15,829 |
|
* Other primarily includes depreciation, patent, software, product testing and other miscellaneous expenses for the three and nine months ended September 30, 2026 and 2025.
|